Article Information
History
- November 20, 2020.
Article Versions
- Version 1 (August 14, 2020 - 10:26).
- Version 2 (September 3, 2020 - 02:54).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Daphna Laifenfeld, PhD1,a,†,
- Chen Yanover, PhD2,b,†,
- Michal Ozery-Flato, PhD3,†,
- Oded Shaham, PhD2,c,
- Michal Rozen-Zvi, PhD3,4,*,
- Nirit Lev, MD/PhD1,d,‡,
- Yaara Goldschmidt, PhD2,e,‡ and
- Iris Grossman, PhD1,f,‡
- 1Formerly Teva Pharmaceuticals Research & Development, Petach Tikva, Israel
- 2Formerly IBM Research – Haifa, Israel
- 3IBM Research – Haifa, Israel
- 4Faculty of Medicine, The Hebrew University, Jerusalem, Israel
- ↵*Corresponding author:
Michal Rosen-Zvi rosen{at}il.ibm.com Haifa University Campus, Mount Carmel Haifa, 3498825, Israel Tel: (972) 04-8296517
Posted November 20, 2020.
Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson’s Disease
